You are here: Industry Insights > cancer

News List

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma prnasia
December 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA® ...
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461 prnasia
December 24, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has received a "Study May Proceed" letter from the US Food and Drug ...
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer pharmaceutical-business-review
December 22, 2020
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and ...
BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Trial for Solid Tumors americanpharmaceuticalreview
December 22, 2020
BioEclipse Therapeutics™ announced the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors.
ICR scientists create 3D protein structure for new therapy development pharmaceutical-technology
December 21, 2020
The UK Institute of Cancer Research, London (ICR) researchers have created a three-dimensional (3D) structure of a complex of molecules for new therapies.
Varian and Yonsei Cancer Center, Yonsei University Health System Sign MOU to Further Innovation to Treat Cancer Patients prnasia
December 16, 2020
Varian today announced that it has entered into a three-year agreement with Yonsei Cancer Center, Yonsei University Health System to collaborate on research and development projects in the field of radiation therapy and oncology.
Draper, Kite Ink Strategic Technology Pact contractpharma
December 16, 2020
Draper entered a multi-year strategic technology collaboration with Kite, a Gilead Company, to enhance Kite’s development of cell therapies using Draper’s engineering services and portfolio of cell bioprocessing technologies.
Boehringer Ingelheim to acquire Labor Dr Merk & Kollegen expresspharma
December 10, 2020
Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP-based cancer immunology treatments.
CR UK makes further cuts in COVID's wake pharmatimes
December 09, 2020
Cancer Research UK has announced further catastrophic cuts in the wake of the coronavirus pandemic, slashing £45 million from its research budget, leaving dozens of potential life-saving projects and hundreds of world-class scientists unfunded.
Axi-cel highly effective in patients with advanced non-Hodgkin lymphoma, finds Phase II trial europeanpharmaceuticalreview
December 08, 2020
Investigators report 76 percent of trial participants had a complete response to axicabtagene ciloleucel (axi-cel), despite being resistant to other therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page